Sugi Predict

Sugi Predict / Targets / BPTF

BPTF

Nucleosome-remodeling factor subunit BPTF · Q12830 · BPTF on Sugi Atlas →

11,448 patent compounds predicted against BPTF, 6,690 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3250048 SCHEMBL3250048 0.54 9/20
SCHEMBL3247038 SCHEMBL3247038 0.52 7/20
SCHEMBL2264937 SCHEMBL2264937 0.47 7/20
SCHEMBL2544338 SCHEMBL2544338 0.45 7/20
SCHEMBL3249795 SCHEMBL3249795 0.66 6/20
SCHEMBL2614925 SCHEMBL2614925 0.55 6/20
SCHEMBL1393228 SCHEMBL1393228 0.51 6/20
SCHEMBL2642056 SCHEMBL2642056 0.46 6/20
SCHEMBL3066937 SCHEMBL3066937 0.62 5/20
SCHEMBL2421817 SCHEMBL2421817 0.56 5/20
SCHEMBL979278 SCHEMBL979278 0.50 5/20
SCHEMBL1581409 SCHEMBL1581409 0.50 5/20
SCHEMBL2869584 SCHEMBL2869584 0.50 5/20
SCHEMBL466352 SCHEMBL466352 0.45 5/20
SCHEMBL1880939 SCHEMBL1880939 0.58 4/20
SCHEMBL2439624 SCHEMBL2439624 0.53 4/20
SCHEMBL181761 SCHEMBL181761 1.00 3/20
SCHEMBL620749 SCHEMBL620749 1.00 3/20
SCHEMBL1719516 SCHEMBL1719516 1.00 3/20
SCHEMBL3421133 SCHEMBL3421133 1.00 3/20

Clinical trials — most relevant to BPTF by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD PHASE3COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC PHASE2NOT_YET_RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Vorinostat in Children PHASE1/PHASE2COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Safety and Pharmacokinetic Profile of CKD-581 PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients nanUNKNOWN
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells. nanUNKNOWN
Family Resilience Initiative Research Program nanUNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy nanNOT_YET_RECRUITING
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Age Related Chromatin Remodelling as a Therapeutic Target for Organ Protection in Cardiac Surgery nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a BPTF binder may also engage these)

ProteinNameSimilarity
Q24K09 — 1.000 Q24K09 →
Q99PI5 — 1.000 Q99PI5 →
Q92539 — 1.000 Q92539 →
P70047 — 1.000 P70047 →
Q8WML3 — 1.000 Q8WML3 →
A0JMK9 — 0.999 A0JMK9 →
Q5HZJ0 — 0.999 Q5HZJ0 →
Q5TKR9 — 0.999 Q5TKR9 →
P13864 — 0.999 P13864 →
KMT5B Histone-lysine N-methyltransferase KMT5B 0.999 landscape →
DNMT1 DNA (cytosine-5)-methyltransferase 1 0.999 landscape →
A6QP06 — 0.999 A6QP06 →
Q9DB00 — 0.998 Q9DB00 →
Q80TZ9 — 0.998 Q80TZ9 →
Q8RWK8 — 0.998 Q8RWK8 →
Q9Z330 — 0.998 Q9Z330 →
Q9NRR4 — 0.998 Q9NRR4 →
Q32KD2 — 0.998 Q32KD2 →
P10244 — 0.998 P10244 →
P58270 — 0.998 P58270 →
A8DZJ1 — 0.998 A8DZJ1 →
Q8C0I4 — 0.998 Q8C0I4 →
Q3T8J9 — 0.998 Q3T8J9 →
O43310 — 0.998 O43310 →
P46200 — 0.998 P46200 →
Q9VGA4 — 0.998 Q9VGA4 →
ZMYND8 MYND-type zinc finger-containing chromatin reader ZMYND8 0.997 landscape →
Q2PFD7 — 0.997 Q2PFD7 →
Q811D2 — 0.997 Q811D2 →
P06537 — 0.997 P06537 →